

Fig. 2. Podoplanin expression and survival in 120 CRC cases at the National Cancer Center Research Hospital. DSS (**a**), DFS (**b**), and liver metastasis-free survival (**c**) of the patients in relation to podoplanin expression ($p = 0.0017$, $p < 0.0001$ and $p = 0.0010$, respectively).

Table 2. Univariate Cox proportional hazards analysis in patients with advanced CRC (stages II and III)

Prognostic factors	Disease-specific survival			Recurrence-free survival			Liver metastasis-free survival		
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Expression of podoplanin (group A/group B)	0.135	0.031–0.586	0.0075	0.128	0.039–0.425	0.0008	0.075	0.010–0.563	0.0118
Age (≥60 years/<60 years)[1]	1.329	0.535–3.306	0.5401	0.711	0.342–1.479	0.3613	0.793	0.306–2.056	0.6328
Gender (male/female)	1.371	0.521–3.607	0.5231	0.847	0.404–1.773	0.6585	0.838	0.319–2.203	0.7205
Tumor location (colon/rectum)	1.210	0.476–3.074	0.6888	0.966	0.461–2.022	0.9259	1.652	0.582–4.690	0.3459
Maximum diameter of the tumor (≥45/<45 mm)[1]	0.703	0.283–1.747	0.4475	0.565	0.267–1.196	0.1353	0.836	0.322–2.166	0.7117
Depth of invasion (T2, T3/T4)	0.207	0.048–0.898	0.0354	0.180	0.054–0.599	0.0052	0.175	0.040–0.771	0.0212
Lymph node metastasis (absence/presence)	0.217	0.063–0.744	0.0151	0.390	0.166–0.913	0.0300	0.527	0.185–1.496	0.2285
Histological grade (G1/G2, G3)	0.634	0.228–1.761	0.3819	0.562	0.240–1.315	0.1836	1.278	0.486–3.357	0.6192
Lymphatic invasion (presence/absence)	1.087	0.361–3.277	0.8819	1.878	0.653–5.397	0.2421	2.189	0.500–9.574	0.2981
Venous invasion (presence/absence)	1.681	0.558–5.066	0.3561	2.325	0.887–6.097	0.0862	7.511	0.996–56.666	0.0505

HR = Hazard ratio; CI = confidence interval. [1] Two groups are divided by the median.



Fig. 3. Podoplanin expression in CCD112CoN fibroblast cells transfected with siRNAs and invasiveness of the cocultured CRC cell lines HCT116 and HCT15. **a** Western blotting using anti-D2-40 antibody (1:100; Dako) in the CCD112CoN fibroblast cells transfected with siRNAs. Podoplanin siRNA reduced podoplanin expression at the protein level almost completely. β-Actin was used as a loading control. **b** Invasiveness of HCT116 and HCT15 cells cocultured with fibroblasts transfected with podoplanin siRNA and control siRNA and in the Matrigel invasion system. After 24 h of coculture, CRC cell lines cocultured with fibroblasts transfected with podoplanin siRNA exhibited a 1.8- to 2.6-fold increase in the number of cells invading the Matrigel-coated insert. HPF = High-power field.

Table 3. Multivariate Cox proportional hazards analysis in patients with advanced CRC (stages II and III)

Prognostic factors	Disease-specific survival			Recurrence-free survival			Liver metastasis-free survival		
	HR	95% CI	p value	HR	95% CI	p value	HR	95% CI	p value
Expression of podoplanin (group A/group B)	0.161	0.037–0.708	0.0157	0.153	0.046–0.510	0.0023	0.089	0.012–0.682	0.0198
Depth of invasion (T2, T3/T4)	0.339	0.075–1.523	0.1582	0.308	0.089–1.066	0.0630	0.396	0.089–1.775	0.2264
Lymph node metastasis (absence/presence)	0.237	0.066–0.849	0.0270	0.488	0.201–1.184	0.1125	0.864	0.297–2.515	0.7888
Venous invasion (presence/absence)	0.858	0.269–2.739	0.7956	1.517	0.551–4.175	0.4194	5.745	0.727–45.380	0.0973

HR = Hazard ratio; CI = confidence interval.

planin, the number of invading cells was significantly increased ($p = 0.027$ and $p = 0.026$, Student's t test for coculture with HCT116 and HCT15, respectively; fig. 3b). As a negative control, when fibroblasts transfected with control siRNA and podoplanin siRNA were cultured only in CM-HT29 without CRC cell lines, almost no invading cells were evident (data not shown).

Discussion

To help understand the difference between CAFs and uninvolved fibroblasts, and to further evaluate the role of CAFs, we compared their genome-wide expression profiles using in vitro CM culture models in which soluble factors originating from cancer cells exerted a paracrine action on the surrounding fibroblasts involved in tumor-

stroma interaction. CM culture models are useful tools for studying interactions between different types of cells, with the advantage that specific signal pathways can be analyzed exclusively [34–37]. Using DNA microarray, we identified podoplanin as a candidate CAF marker molecule among upregulated genes.

Podoplanin is one of a family of glycoproteins that are well known to be involved in many cellular activities in embryogenesis and development, and are particularly important in diseases such as cancer [16]. Mucin-like transmembrane glycoproteins have been found in epithelial and nonepithelial tissues, and can exert a protective role against environmental agents as well as possessing other biological activities. For example, several membrane-associated mucins are involved in cell-cell interactions and mediate leukocyte trafficking, thrombosis and inflammation [38–40]. In general, mucin-type glycoproteins have an extended brush-like conformation due to their extensive O-glycosylation [39]. This highly negatively charged structure is relatively resistant to proteases and provides a physical barrier protecting cells from environmental agents.

In the present study, immunohistochemical localization of podoplanin was confined exclusively to CAFs in the cancer stroma. Normal stroma, epithelial cells and tumor cells were completely negative for podoplanin in all cases tested, and only lymphatic vessels were positive. Podoplanin expression in CAFs of cancer stroma was significantly correlated with more distal tumor localization and a shallower depth of tumor invasion. Invasion of CRC cell lines was augmented upon coculture with fibroblasts in which podoplanin expression was reduced by siRNA. These results indicate that podoplanin could play an important protective role against cancer invasion.

Expression of podoplanin by cancer cells of oral and uterine cervix squamous cell carcinoma has been reported to be associated with prognosis [41, 42]. However, previous studies have found that adenocarcinoma cells rarely express podoplanin [43, 44]. Podoplanin-positive CAFs are reportedly present in invasive adenocarcinoma of the lung, but not in noninvasive adenocarcinoma [45]. Podoplanin expression by CAFs is reported to be significantly associated with a poor outcome in patients with lung adenocarcinoma. However, multivariate analysis failed to show that podoplanin expression was an independent prognostic factor [45]. In the present study, the localization of podoplanin expression was intriguing because it was seen in CAFs located mainly in the superficial to deep area of the tumor, sparing the invasive front where tumor budding is often observed. No podoplanin expression was observed in the normal stromal cells, except for lymphatic vessels. Tumor budding is well known to be relevant to metastatic acitivity and outcome in patients with CRC, and is usually found at the invasive front [46, 47]. Therefore the characteristic localization of podoplanin expression in tumors, sparing the invasive front, in addition to the resistance of podoplanin to proteases and its role as a physical barrier against environmental agents [39], supports the idea that podoplanin could play an important protective role against cancer invasion. Furthermore, multivariate analysis using the Cox proportional hazards model for DSS revealed that podoplanin expression and pN were significantly associated with prognosis when adjusted for pT and venous invasion. Multivariate analysis of both DFS and liver metastasis-free survival revealed that only podoplanin expression was associated with prognosis when adjusted for pT, pN, and venous invasion. These findings suggest that increased expression of podoplanin in CAFs is a good prognostic factor in patients with advanced CRC, indicating the defensive role of podoplanin against tumor invasion. In terms of clinical use, podoplanin expression in CRC might be helpful for selecting patients who should undergo adjuvant chemotherapy, or those for whom it is unnecessary. However, in order for podoplanin expression to be applied for practical clinical care, it must be validated in a large-scale prospective clinical trial.

Furthermore, our coculture invasion assay indicated that podoplanin expressed in CAFs could have a suppressive effect on the invasion of tumor cells, although it is not yet clear whether CAFs have both an inductive and a suppressive effect on tumor progression and regulate tumorigenesis. Other constituents of the desmoplastic extracellular matrix have also been shown to inhibit tumor progression. For example, injection of L-3, 4-dehydroproline, which inhibits the formation of collagen fibrils, increases tumor cell invasion in mice with B16F10 melanoma subcutaneous tumors [48]. In addition, extracellular matrix accumulation in tumors contributes to increased interstitial fluid pressure and hinders the diffusion of macromolecules and oxygen, leading to tumor cell necrosis [49, 50]. The overall effect of altered extracellular matrix in tumors and the effect of CAFs during tumor progression are still poorly understood. Further studies directed at disrupting the complex interaction between tumor cells and stromal composition may define new strategies for diagnosis of tumors and suitable therapeutic interventions.

In conclusion, podoplanin, a mucin-type transmembrane glycoprotein, was found to be upregulated in CAFs

in vitro and to be overexpressed in CAFs surrounding CRC cells in vivo. Multivariate analysis of both DFS and liver metastasis-free survival revealed that only podoplanin expression was associated with prognosis when adjusted for pT, pN, and venous invasion. In addition, invasiveness of CRC cells was increased significantly by coculture with podoplanin-suppressed CAFs. These findings suggest that increased podoplanin expression in stromal fibroblasts is a significant indicator of good prognosis in patients with advanced CRC, reflecting its defensive role against cancer invasion.

Acknowledgement

This study was supported by a grant-in-aid for the Third Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labor and Welfare of Japan. T. Y. is a recipient of a Research Resident Fellowship from the Foundation for Promotion of Cancer Research in Japan.

References

1 Bhowmick NA, Neilson EG, Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332–337.
2 De Wever O, Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 2003;200:429–447.
3 Kalluri R, Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 2006;6:392–401.
4 Micke P, Ostman A: Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 2005;9:1217–1233.
5 Bhowmick NA, Chytil A, Plieth D, et al: TGF-β signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 2004;303:848–851.
6 Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335–348.
7 Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR: Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 1999;59:5002–5011.
8 Dimanche-Boitrel MT, Vakaet L Jr, Pujuguet P, et al: In vivo and in vitro invasiveness of a rat colon-cancer cell line maintaining E-cadherin expression: an enhancing role of tumor-associated myofibroblasts. Int J Cancer 1994;56:512–521.
9 Sternlicht MD, Lochter A, Sympson CJ, et al: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999;98:137–146.
10 Lochter A, Galosy S, Muschler J, Freedman N, Werb Z, Bissell MJ: Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol 1997;139:1861–1872.
11 Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS: Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. Proc Natl Acad Sci USA 1991;88:6028–6032.
12 Mishima K, Kato Y, Kaneko MK, Nishikawa R, Hirose T, Matsutani M: Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol (Berl) 2006;111:483–488.
13 Yuan P, Temam S, El-Naggar A, et al: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006;107:563–569.
14 Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M: Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. Am J Pathol 2005;166:913–921.
15 Zimmer G, Oeffner F, Von Messling V, et al: Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium. Biochem J 1999;341:277–284.
16 Brockhausen I, Schutzbach J, Kuhns W: Glycoproteins and their relationship to human disease. Acta Anat (Basel) 1998;161:36–78.
17 Martin-Villar E, Scholl FG, Gamallo C, et al: Characterization of human PA2.26 antigen (T1α-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer 2005;113:899–910.
18 Ordonez NG: Podoplanin: a novel diagnostic immunohistochemical marker. Adv Anat Pathol 2006;13:83–88.
19 Breiteneder-Geleff S, Soleiman A, Kowalski H, et al: Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999;154:385–394.
20 Schacht V, Ramirez MI, Hong YK, et al: T1α/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. Embo J 2003;22:3546–3556.
21 Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G: Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 2006;9:261–272.
22 Sugimoto Y, Watanabe M, Oh-hara T, Sato S, Isoe T, Tsuruo T: Suppression of experimental lung colonization of a metastatic variant of murine colon adenocarcinoma 26 by a monoclonal antibody 8F11 inhibiting tumor cell-induced platelet aggregation. Cancer Res 1991;51:921–925.
23 Watanabe M, Okochi E, Sugimoto Y, Tsuruo T: Identification of a platelet-aggregating factor of murine colon adenocarcinoma as determined by monoclonal antibodies. Cancer Res 1988;48:6411–6416.
24 Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, Osawa M: Enhanced expression of Aggrus (T1α/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 2005;26:195–200.
25 Kimura N, Kimura I: Podoplanin as a marker for mesothelioma. Pathol Int 2005;55:83–86.
26 Ordonez NG: D2–40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372–380.
27 Roy S, Chu A, Trojanowski JQ, Zhang PJ: D2–40, a novel monoclonal antibody against the M2A antigen as a marker to distinguish hemangioblastomas from renal cell carcinomas. Acta Neuropathol (Berl) 2005;109:497–502.

28 Kato Y, Sasagawa I, Kaneko M, Osawa M, Fujita N, Tsuruo T: Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene 2004;23:8552–8556.
29 Shibahara J, Kashima T, Kikuchi Y, Kunita A, Fukayama M: Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Arch 2006;448:493–499.
30 Mishima K, Kato Y, Kaneko MK, et al: Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathol (Berl) 2006;111: 563–568.
31 Gandarillas A, Scholl FG, Benito N, Gamallo C, Quintanilla M: Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Mol Carcinog 1997; 20:10–18.
32 Sobin LH, Fleming ID: TNM Classification of Malignant Tumors, ed 5 (1997). Union Internationale contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803–1804.
33 World Health Organization: Classification of Tumours. Lyon, IARC Press, 2000.
34 DeCosse JJ, Gossens C, Kuzma JF, Unsworth BR: Embryonic inductive tissues that cause histologic differentiation of murine mammary carcinoma in vitro. J Natl Cancer Inst 1975;54:913–922.
35 DeCosse JJ, Gossens CL, Kuzma JF, Unsworth BR: Breast cancer: induction of differentiation by embryonic tissue. Science 1973;181:1057–1058.
36 Cooper M, Pinkus H: Intrauterine transplantation of rat basal cell carcinoma as a model for reconversion of malignant to benign growth. Cancer Res 1977;37:2544–2552.
37 Maehara N, Matsumoto K, Kuba K, Mizumoto K, Tanaka M, Nakamura T: NK4, a four-kringle antagonist of HGF, inhibits spreading and invasion of human pancreatic cancer cells. Br J Cancer 2001;84:864–873.
38 Gendler SJ, Spicer AP: Epithelial mucin genes. Annu Rev Physiol 1995;57:607–634.
39 Hilkens J, Ligtenberg MJ, Vos HL, Litvinov SV: Cell membrane-associated mucins and their adhesion-modulating property. Trends Biochem Sci 1992;17:359–363.
40 Varki A: Selectin ligands. Proc Natl Acad Sci USA 1994;91:7390–7397.
41 Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, Mao L: Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer 2006;107: 563–569.
42 Dumoff KL, Chu CS, Harris EE, Holtz D, Xu X, Zhang PJ, ACS G: Low podoplanin expression in pretreatment biopsy material predicts poor prognosis in advanced-stage squamous cell carcinoma of the uterine cervix treated by primary radiation. Mod Pathol 2006;19:708–716.
43 Ordonez NG: D2–40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372–380.
44 Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ: Utility of D2–40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105–110.
45 Kawase A, Ishii G, Nagai K, Ito T, Nagano T, Murata Y, Hishida T, Nishimura M, Yoshida J, Suzuki K, Ochiai A: Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 2008;123:1053–1059.
46 Okuyama T, Oya M, Ishikawa H: Budding as a risk factor for lymph node metastasis in pT1 or pT2 well-differentiated colorectal adenocarcinoma. Dis Colon Rectum 2002;45: 628–634.
47 Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC: A new prognostic staging system for rectal cancer. Ann Surg 2004;240:832–839.
48 Barsky SH, Gopalakrishna R: Increased invasion and spontaneous metastasis of BL6 melanoma with inhibition of the desmoplastic response in C57 BL/6 mice. Cancer Res 1987;47:1663–1667.
49 Netti PA, Berk DA, Swartz MA, Grodzinsky AJ, Jain RK: Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000;60:2497–2503.
50 Brown EB, Boucher Y, Nasser S, Jain RK: Measurement of macromolecular diffusion coefficients in human tumors. Microvasc Res 2004;67:231–236.

Cancer Science
The official journal of the Japanese Cancer Association JCA

DNA methylation of interferon regulatory factors in gastric cancer and noncancerous gastric mucosae

Masaki Yamashita,[1,2,3] Minoru Toyota,[2,9] Hiromu Suzuki,[2,4] Masanori Nojima,[5] Eiichiro Yamamoto,[2,4] Seiko Kamimae,[2] Yoshiyuki Watanabe,[1] Masahiro Kai,[2] Hirofumi Akashi,[6] Reo Maruyama,[3,4] Yasushi Sasaki,[3] Hiroo Yamano,[7] Tamotsu Sugai,[8] Yasuhisa Shinomura,[4] Kohzoh Imai,[4] Takashi Tokino[3] and Fumio Itoh[1,9]

[1]Department of Gastroenterology and Hepatology, St. Marianna Medical University, School of Medicine, Kawasaki; Departments of [2]Biochemistry and [3]Molecular Biology, Cancer Research Institute, [4]First Department of Internal Medicine, [5]Department of Public Health, [6]Scholarly Communication Center, Sapporo Medical University, Sapporo; [7]Department of Gastroenterology, Akita Red Cross Hospital, Akita; [8]Department of Pathology, Iwate Medical University, Morioka, Japan

(Received December 22, 2009/Revised March 22, 2010/Accepted March 23, 2010/Accepted manuscript online April 2, 2010)

Interferon regulatory factors (IRFs) are transcription factors known to play key roles in innate and adaptive immune responses, cell growth, apoptosis, and development. Their function in tumorigenesis of gastric cancer remains to be determined, however. In the present study, therefore, we examined epigenetic inactivation of *IRF1–9* in a panel of gastric cancer cell lines. We found that expression of *IRF4*, *IRF5*, and *IRF8* was frequently suppressed in gastric cancer cell lines; that methylation of the three genes correlated with their silencing; and that treating the cells with the demethylating agent 5-aza-2′-deoxycytidine (DAC) restored their expression. Expression of *IRF5* in cancer cells was enhanced by the combination of DAC treatment and adenoviral vector-mediated expression of p53, p63, or p73. Interferon-γ-induced expression of *IRF8* was also enhanced by DAC. Moreover, treating gastric cancer cells with DAC enhanced the suppressive effects of interferon-α, interferon-β, and interferon-γ on cell growth. Among a cohort of 455 gastric cancer and noncancerous gastric tissue samples, methylation of *IRF4* was frequently observed in both gastric cancer specimens and noncancerous specimens of gastric mucosa from patients with multiple gastric cancers, which suggests *IRF4* methylation could be a useful molecular marker for diagnosing recurrence of gastric cancers. Our findings indicate that epigenetic *IRF* inactivation plays a key role in tumorigenesis of gastric cancer, and that inhibition of DNA methylation may restore the antitumor activity of interferons through up-regulation of *IRFs*. (*Cancer Sci* 2010)

Gastric cancer arises through the accumulation of multiple genetic changes, including mutation of *adenomatous polyposis coli* (*APC*), *K-ras*, and *p53*.[1] But recent studies have also shown that epigenetic changes such as DNA methylation are also importantly involved in the gene silencing seen in cancer.[2] For instance, genes involved in regulation of the cell cycle and apoptosis are now known to be inactivated by DNA methylation.[3–5] In addition we previously showed that a number of genes involved in signal transduction are epigenetically silenced in cancer. The affected genes include *secreted frizzled-related protein 1* (*SFRP1*), *SFRP2*, *dickkopf 1* (*DKK1*), and *DKK2*, which are negative regulators of WNT signaling,[6,7] *Ras association domain family member 2* (*RASSF2*), a negative regulator of Ras;[8] and *14-3-3σ* and *deafness, autosomal dominant 5* (*DFNA5*), two transcriptional targets of p53.[9,10] Because DNA methylation is an epigenetic change, which does not affect gene sequences, the silenced genes can be reactivated by demethylation, making DNA methylation a useful target of cancer therapy.[11,12]

DNA methylation could also be used as a molecular marker for cancer detection. For instance, methylation of genes such as *SFRP2* and *GATA binding protein-4* (*GATA-4*) has been detected in stool DNA from colorectal cancer patients.[13,14] In gastric cancer, infection by *Helicobacter pylori* (*H. pylori*) induces DNA methylation even in noncancerous tissues.[15] In addition, higher levels of methylation are detected in gastric mucosae from cancer patients than in samples from patients without cancer.[15,16] Thus, DNA methylation in noncancerous tissues could be a potentially useful marker predicting development or recurrence of gastric cancer.

The interferon regulatory factor gene (*IRF*) family encodes a group transcription factors induced by interferon. To date, nine *IRF*s (*IRF1–9*) have been identified (reviewed in ref. 17), and their products have been shown to be involved in variety of processes, including innate and adaptive immune responses, cell growth, apoptosis, and development.[17] Interferon regulatory factor 1 (IRF1) was the first to be identified as a regulatory factor in the interferon system,[18] and several lines of evidence suggest IRF1 acts as a tumor suppressor in human neoplasias. For instance, IRF1 and p53 cooperate via two parallel but independent pathways leading to the induction of cell cycle arrest and p21 gene transcription.[19] In addition, IRF5 is induced by p53 and is involved in growth suppression,[20,21] while both IRF5 and IRF7 are involved in the induction of senescence.[22] And down-regulation of *IRF8* expression contributes to resistance to apoptosis and to the metastatic phenotype in metastatic tumor cells.[23] These findings prompted us to speculate that epigenetic inactivation of *IRF* expression may play a key role in tumorigenesis.

Epigenetic inactivation of *IRF8* has recently been observed in colorectal, nasopharyngeal, esophageal, breast, and cervical cancers,[23,24] and inactivation of *IRF4* was shown to be silenced by DNA methylation in chronic myeloid leukemia.[25] Thus epigenetic inactivation of *IRFs* appears to be centrally involved in the development of human neoplasias. However, there has been no comprehensive analysis of the epigenetic alterations of *IRFs* in gastric cancer. In the present study, therefore, we examined epigenetic inactivation of *IRF1–9* in gastric cancer.

Materials and Methods

Cell lines and specimens. Sixteen gastric cancer cell lines (MKN1, MKN7, MKN28, MKN45, MKN74, KatoIII, AZ521, JRST, SNU1, SNU16, NUGC3, NUGC4, AGS, NCI-N87, SNU16) were obtained from the American Type Culture Collection (Manassas, VA, USA) or the Japanese Collection of Research Bioresources (Tokyo, Japan). In addition, SH101 cells were kindly provided by Dr K. Yanagihara[26] at the National Cancer Center Research Institute and have been described previously. In some cases cancer cell lines were treated with 2 μM 5-aza-2′-deoxycytidine (DAC) (Sigma, St. Louis, MO, USA) for

[9]To whom correspondence should be addressed.
E-mail: mtoyota@sapmed.ac.jp; fitoh@marianna-u.ac.jp

doi: 10.1111/j.1349-7006.2010.01581.x

72 h, replacing the drug and medium every 24 h. When cells were exposed to DAC and either IFN-α, IFN-β, or IFN-γ, 1000 U/mL IFN-α or IFN-β or 100 U/mL IFN-γ was added to the culture for 48 h following incubation with 0.2 μM DAC. The generation and purification of replication-deficient recombinant adenoviruses encoding p53 (Ad-p53), p63 (Ad-p63), p73 (Ad-p73), or LacZ (Ad-LacZ), as well as the infection procedure, were all described previously.[27,28] At a multiplicity of infection (MOI) of 100, 90–100% of the cells were infected.

Two sets of specimens were used in this study. One set contained a total of 68 primary gastric cancers and 22 corresponding gastric mucosa specimens described previously.[29] The second set contained 35 gastric cancer specimens and 330 noncancerous specimens of gastric mucosa from 165 patients, which were obtained through biopsy during the course of endoscopy. Informed consent was obtained from all patients before collection of the specimens. Genomic DNA was extracted using the standard phenol-chloroform procedure. Total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and then treated with a DNA-free kit (Ambion, Austin, TX, USA). Total RNA extracted from normal stomach, colon, breast, and pancreas from a healthy individual was purchased from BioChain (Hayward, CA, USA). RNA was also obtained from normal stomach glands using the crypt isolation technique as described previously.[30]

Gene expression analysis. Real-time PCR was carried out using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA, USA) and a 7900HT Fast Real-Time PCR System (Applied Biosystems) according to the manufacturer's instructions. SDS2.2.2 software (Applied Biosystems) was used for comparative delta Ct analysis, and *GAPDH* served as an endogenous control. The primers used in this study are shown in Supplementary Table S1. The TaqMan primers/probes used in this study were: *IRF1*, Hs00971960_m1; *IRF2*, Hs01082884_m1; *IRF3*, Hs00155574_m1; *IRF4*, Hs00180031_m1; *IRF5*, Hs00158114_m1; *IRF6*, Hs00608402_m1; *IRF7*, Hs00242190_g1; *IRF8*, Hs00175238_m1; and *IRF9*, Hs00196051_m1.

Methylation analysis. Samples of genomic DNA (2 μg) were modified with sodium bisulfite using an EpiTect Bisulfite Kit (Qiagen, Hilden, Germany). Methylation was determined by



Fig. 1. Down-regulation of interferon regulatory factors (*IRFs*) in gastric cancer cell lines. The heat map shows the expression profiles in 16 gastric cancer cell lines (a) and four normal tissue specimens (b). Levels of expression are normalized to *GAPDH*, and delta-CT values are shown. (c) Analysis of *IRF1–8* methylation in gastric cancer cell lines. Methylation of 5′ CpG islands was examined using methylation-specific PCR. The cell lines examined are shown on the top. DNMT KO: DNMT1$^{-/-}$, DNMT3B$^{-/-}$ HCT116 cell. IVD, *in vitro* methylated DNA; M, methylated; N, stomach: normal stomach; U, unmethylated.

doi: 10.1111/j.1349-7006.2010.01581.x

methylation specific PCR, bisulfite-sequencing, and bisulfite-pyrosequencing, and details of methods are shown in the Supporting Information. The primer sequences are listed in Supplementary Tables S1 and S2.

Statistics. Statistical analyses were carried out using SPSSJ 15.0 (SPSS Japan, Tokyo, Japan). For comparison of methylation levels between cancerous and normal tissues, and for other continuous data, *t*-tests or paired *t*-tests were performed, as appropriate. Fisher's exact test and the Mann–Whitney *U*-test were used to evaluate the association between *IRF* methylation, clinicopathological features, and other genetic and epigenetic alterations. Receiver–operator curves (ROC) were constructed based on *IRF* methylation levels, and *P*-values were calculated by comparing the areas under the curves (AUC) with a reference curve. Values of $P < 0.05$ were considered significant.

Mutation of p53 and KRAS and detection of the presence of CpG island methylator phenotype (CIMP) or Epstein–Barr virus (EBV) were described previously.[31] To determine CIMP status, methylation status of five loci (MINT1, MINT2, MINT12, MINT25, and MINT31) was assessed using combined bisulfite restriction analysis (COBRA). Cases with methylation of four or five loci were defined as CIMP-H. Cases with methylation of one to three loci were defined as CIMP-L. Cases with no methylation were defined as CIMP-N.

Results

Expression of *IRF1–9* in gastric cancer cell lines. To determine whether expression of *IRF1–9* is altered in gastric cancers, we carried out a real-time PCR analysis using a panel of gastric cancer cell lines (Fig. 1a). We found that expression of *IRF4*, *IRF5*, and *IRF8* was frequently down-regulated in these cell lines. Expression of *IRF7* was not detected in normal tissues or in the gastric cancer cell lines, but the remaining *IRFs* were expressed at various levels in normal tissues (Fig. 1a,b). We also examined expression of *IRF1-9* using cDNA prepared using the gastric gland isolation technique, and similar levels of *IRF1–9* expression were observed (Fig. 1b). To determine whether the



Fig. 2. Methylation analysis of interferon regulatory factor (*IRF*)-*4* in gastric cancer cell lines. (a) Representative pyrosequencing results. Gray columns depict regions of CpG sites, and the percentage methylation at each CpG site is shown on the top. (b) Representative bisulfite-sequencing results. Each circle represents a CpG dinucleotide. Methylation status: open circles, unmethylated; black circles, methylated. The cell lines examined are shown below the columns.

down-regulation of the affected *IRFs* reflected epigenetic modification, we next assessed *IRF* expression following treatment with the demethylating agent DAC. We found that DAC restored *IRF* expression in most gastric cancer cell lines showing *IRF4*, *IRF5*, and/or *IRF8* methylation (Fig. S1). On the other hand, DAC had little effect on several cell lines (i.e. AZ521, AGS, for *IRF5*; NUGC3 for *IRF8*), suggesting other stimuli may be required for full reactivation of *IRFs*.

Treating cancer cells with DAC restored induction of *IRF5* by p53 and of *IRF8* by IFN-γ. Interferon regulatory factor 5 (*IRF5*) and *IRF8* are known to be transcriptional targets of p53[21] and interferon-γ,[32] respectively. We therefore tested whether DAC would enhance the induction of *IRF5* by p53 family members in two gastric cancer cell lines showing *IRF5* methylation. When we infected MKN74 and SNU1 cells with Ad-lacZ, Ad-p53, Ad-p73, or Ad-p63, DAC acted synergistically with the expressed p53 family member to induce *IRF5* expression in the cells (Fig. S2a). In similar fashion, we found that treating MKN28 cells with DAC enhanced the induction of *IRF8* by interferon-γ (Fig. S2b).

Methylation of *IRF4*, *IRF5*, and *IRF8* in gastric cancer cell lines. Database analysis of nine *IRF* genes showed that all except *IRF9* contained CpG islands at their 5′ ends. We therefore used methylation-specific PCR to examine the methylation status of *IRF1-8* (Fig. 1c). We found that *IRF4* was the most frequently methylated in gastric cancer cell lines. In addition, methylation of *IRF5*, *IRF6*, *IRF7*, and *IRF8* was detected in subsets of gastric cancer cell lines. No methylation of *IRF1*, *IRF2*, or *IRF3* was detected in any of the gastric cancer cell lines tested.

We next carried out bisulfite-pyrosequencing to further examine the role of DNA methylation in the down-regulation of *IRF* expression (Figs 2a,3a,4a). Gastric cancer cell lines that exhibited low or negligible *IRF4* expression showed high levels of methylation. Similarly, methylation was well correlated with the down-regulation of *IRF5* and *IRF8* in gastric cancer cell lines.

We then confirmed the methylation status of *IRF4*, *IRF5*, and *IRF8* using bisulfite-sequencing (Figs 2b,3b,4b). High levels of *IRF4* methylation were detected in all of the cancer cell lines tested. In the gastric cancer cell lines, for example, heterogeneous methylation was observed in the region spanning positions −50 to −100 from the transcription start site. High levels of *IRF5* methylation were detected in two (MKN28 and MKN74) of the cancer cell lines showing low or negligible expression, but only sparse methylation was detected in a third (MKN7). MKN7 cells expressed *IRF8* and did not show methylation of that gene. By contrast, MKN28 and MKN74 cells did not express *IRF8* and showed dense methylation of the gene.

Suppression of cell growth by DAC + IFN. Given that DAC induces *IRFs* in gastric cancer cells, we tested whether DAC treatment would enhance the growth suppressive effect of interferon on cancer cells. When we treated four gastric cancer cell lines (SNU1, MKN28, KatoIII, and MKN74) first with DAC for 72 h and then with IFN-α, -β, or -γ for 48 h, we found that DAC enhanced the growth suppressive effects of all three interferons (Fig. S3). This prompted us to test the effect of IFN on



Fig. 3. Methylation analysis of interferon regulatory factor (*IRF*)-5 in gastric cancer cell lines. (a) Representative pyrosequencing results. (b) Representative bisulfite-sequencing results.

doi: 10.1111/j.1349-7006.2010.01581.x

DNA methylation. Using bisulfite-pyrosequencing with DNA from cells treated with DAC and/or IFN (Fig. S4), we found that although treatment with DAC induced partial demethylation of *IRF4*, *IRF5*, and *IRF8*, treatment with IFN-$\alpha/\beta/\gamma$, alone or in combination with DAC, did not induce further demethylation in MKN74 cells.

Methylation of *IRF4*, *IRF5*, and *IRF8* in primary gastric cancers. To assess *IRF* methylation in primary tumors, we used bisulfite-pyrosequencing to examine primary specimens from 68 gastric cancers and 22 noncancerous gastric tissues (Fig. 5a,b). We found that *IRF4* was frequently methylated in gastric cancer. In addition, we detected high levels of *IRF5* methylation in several gastric cancers, but the average methylation levels did not significantly differ between the cancerous and normal tissues. We did not detect significant methylation of *IRF8* in primary gastric cancers.

We next evaluated the correlation between *IRF* methylation and the clinicopathological features of gastric cancers and between *IRF* methylation and other genetic and epigenetic alterations in gastric cancer. We selected a 13.9% cut-off for *IRF4* and a 16.6% cut-off for *IRF5* methylation based on our finding that these levels represent the 75th percentile among the control samples. With those thresholds, 64 of 68 cases showed methylation of *IRF4*, and 11 of 68 cases showed methylation of *IRF5* (Fig. 5c). Methylation of *IRF4* was detected significantly more frequently in diffuse type and CIMP-H gastric cancers than in CIMP-L or CIMP-N cancers. Methylation of *IRF5* was detected significantly more frequently in gastric cancers positive for EBV and in CIMP-H cancers than in CIMP-L or CIMP-N cancers (Table 1).

Methylation of *IRF4* in noncancerous gastric mucosa is a potential molecular marker for gastric cancer. Several of the cases studied showed high levels of *IRF4* methylation, even in noncancerous gastric mucosa (Fig. 5b). We therefore wondered whether levels of *IRF4* methylation in noncancerous tissues are associated with the presence of gastric cancer. To address that issue, we examined tissue specimens obtained from 165 patients through endoscopic biopsy, including 35 gastric cancer specimens and 330 noncancerous specimens of gastric mucosa (Fig. 6a, Table S3). We found that methylation of *IRF4* in noncancerous gastric tissues was significantly higher in patients with cancer than in those without cancer ($P < 0.001$). In addition, patients with multiple gastric cancers showed significantly higher levels of *IRF4* methylation than patients with a single cancer ($P < 0.05$). Levels of *IRF4* methylation tended to be higher in patients infected with *H. pylori* than in those without *H. pylori*, though the difference was not statistically significant.

The clinical usefulness of DNA methylation for distinguishing cancer patients from noncancer patients was confirmed by ROC analysis. Methylation of *IRF4* gave highly discriminative



Fig. 4. Methylation analysis of interferon regulatory factor (*IRF*)-*8* in gastric cancer cell lines. (a) Representative pyrosequencing results. (b) Representative bisulfite-sequencing results.



Fig. 5. Methylation of interferon regulatory factor (*IRF*)-*4*, *IRF5*, and *IRF8* in primary gastric cancers. (a) Representative bisulfite-pyrosequencing results. (b) Scatter plot of *IRF* methylation. GC, gastric cancer; horizontal bars, average methylation levels in total cases; N, normal stomach; NS, not significant. (c) Genetic and epigenetic alterations in gastric cancer. Each row represents the separate gene locus shown on the left. Each column is a primary gastric cancer: red rectangles, methylated tumors; purple rectangles, mutated tumors, grey rectangles, Epstein–Barr virus-positive tumors.

ROC profiles, which clearly distinguished patients with a single gastric cancer from *H. pylori*-positive gastritis patients without cancer (AUC: 0.77, $P < 0.001$) (Fig. S5, Table S3). They also distinguished patients with a single or multiple gastric cancers from *H. pylori*-positive gastritis patients without cancer (AUC: 0.81, $P < 0.001$) (Fig. S6, Table S3). More interestingly, when 32% *IRF4* methylation in noncancerous gastric mucosae was used as the cut-off, patients with multiple gastric cancers could be discriminated from patients with a single gastric cancer with a sensitivity of 87% and a specificity of 63% (AUC: 0.74, $P < 0.05$) (Fig. 6b, Table S3). This suggests methylation of *IRF4* in noncancerous gastric mucosae could be used as a molecular marker to predict recurrence of gastric cancer.

Discussion

Interferons play critical roles in regulating immune system function, cell growth, and apoptosis. It is therefore noteworthy that expression of interferon target genes is suppressed in a variety of cancers.[33] For instance, signaling pathways mediated by expression of *signal transducer and activator of transcription 1* (*STAT1*),[34] *class II major histocompatibility complex transactivator* (*CIITA*),[35] and *XIAP associated factor 1* (*XAF1*),[36] three genes downstream of interferon, are silenced by epigenetic inactivation in various cancers, which suggests impairment of interferon signaling by epigenetic mechanisms may play an important role in tumorigenesis. Consistent with that idea, a number of earlier studies have shown that *IRFs* are silenced by DNA methylation in human neoplasias.[23–25,37,38] Here, we found that DNA methylation of *IRF4*, *IRF5*, and/or *IRF8* is a frequent event in gastric cancer cell lines and that treatment with a demethylating agent (DAC) restores induction of *IRF5* by p53, p63, or p73 and induction of *IRF8* by IFN-γ, which confirms the role played by DNA methylation in silencing the genes. Moreover, when applied together, interferon and DAC acted synergistically to suppress cell growth. Thus inhibition of DNA methylation could be a useful strategy for enhancing the tumor suppressor activity of interferon.

doi: 10.1111/j.1349-7006.2010.01581.x

Table 1. Correlation between methylation of IRF4/IRF5 and the clinicopathological features of the patients

Characteristics		IRF4			IRF5		
	Total	*U*	M	*P*-value	*U*	M	*P*-value
n	68	4	64		57	11	
Age							
Mean	64.2	66.3	64.0	0.727	64.5	62.7	0.668
SD	12.1	6.7	12.4		11.7	14.9	
Sex							
Male	45	4	41	0.292	19	4	1.000
Female	23	0	23		38	7	
Location							
Lower	30	2	28	0.929	26	4	0.458
Middle	23	1	22		20	3	
Upper	15	1	14		11	4	
Type							
0	4	0	4	0.605	3	1	0.547
1	5	0	5		4	1	
2	26	3	23		20	6	
3	25	1	24		22	3	
4	8	0	8		8	0	
Histology							
D	38	0	38	0.034	29	9	0.096
I	30	4	26		28	2	
ly							
–	14	0	16	0.566	12	4	0.272
+	44	4	48		45	7	
v							
–	16	0	33	0.115	27	6	0.749
+	52	4	31		30	5	
pT							
pT1	5	0	5	0.225	4	1	0.352
pT2	36	1	35		29	7	
pT3	25	3	22		22	3	
pT4	2	0	2		2	0	
pN							
pN0	18	2	16	0.145	16	2	0.855
pN1	25	2	23		19	6	
pN2	14	0	14		12	2	
pN3	11	0	11		10	1	
pM							
M0	57	4	53	1.000	47	10	0.677
M1	11	0	11		10	1	
Stage (pTNM, 1997, 5th ed)							
1A	3	0	3	0.342	2	1	0.511
1B	12	0	12		11	1	
2	13	3	10		10	3	
3A	12	1	11		9	3	
3B	7	0	7		6	1	
4	21	0	21		19	2	
KRAS							
–	64	4	60	1.000	55	9	0.120
+	4	0	4		2	2	
p53							
–	53	3	50	1.000	42	11	0.105
+	15	1	14		15	0	
EBV							
–	60	4	56	1.000	55	5	<0.001
+	8	0	8		2	6	
CIMP							
H	17	0	14	0.035	8	9	<0.001
L	34	1	33		32	2	
N	17	3	14		17	0	

CIMP, CpG island methylator phenotype; EBV, Epstein–Barr virus; IRF4, interferon regulatory factor 4. ly, lymphatic vessels invasion; pN, pathological node stage; pT, pathological tumor stage; pM, pathological metastasis.



Fig. 6. Methylation levels of interferon regulatory factor (*IRF*)-*4* in gastric cancers and noncancerous gastric mucosae. (a) Distribution of *IRF4* methylation in gastric cancer and noncancerous gastric mucosae. GC, gastric cancer; HP(+), gastric mucosae from *Helicobacter pylori* (*H. pylori*)-positive chronic gastritis patients without cancer; HP(–), gastric mucosae from *H. pylori*-negative chronic gastritis patients without cancer; NGC-M, noncancerous gastric mucosae from multiple gastric cancer patients; NGC-S, noncancerous gastric mucosae from single gastric cancer patients. For noncancerous gastric mucosae, specimens were obtained from the antrum and body, and average methylation levels are shown. Horizontal bars, average methylation levels in total cases. The numbers of cases examined in the study are shown below the column. (b) Receiver–operator curve (ROC) for *IRF4* methylation to discriminate patients with multiple gastric cancers from patients with a single gastric cancer.

It was previously shown that *IRF4* is silenced by DNA methylation in chronic myeloid leukemia.[25] In the present study, we found that *IRF4* is frequently silenced by DNA methylation in both gastric cancers and noncancerous gastric mucosae from cancer patients. Such methylation can be readily detected in serum samples and gastric washing solution,[39,40] and the high frequency of *IRF4* methylation in gastric cancer could be useful for establishing a diagnostic system with DNA methylation as the target. The precise role of *IRF4* methylation in the development and progression of gastric cancer remains unknown. It has been suggested that weakly expressed genes are especially susceptible to methylation changes in cancer.[41] In fact, we found that *IRF4* expression was minimally expressed in gastric epithelium, which consistent with the report that *IRF4* is exclusively expressed in lymphocytic tissues.[17] If that is the case, methylation of *IRF4* may not provide a growth advantage to cells, but may reflect epigenetic defects in the gastric mucosa caused by inflammation. Here we showed that levels of *IRF4* methylation were high in noncancerous gastric mucosae from gastric cancer patients, especially

in those with multiple cancers. Although further prospective study may be necessary, it would appear that methylation of *IRF4* could be a molecular marker with which to predict the development or recurrence of gastric cancer.

Several lines of evidence have suggest that IRF5 has tumor suppressor activity, and that in response to DNA damage *IRF5* is induced by p53 to promote cell cycle arrest and apoptosis.[20,21,42] Kulaeva *et al.*[43]showed that treating spontaneously immortal Li–Fraumeni fibroblasts with DAC induces a senescence-like state, and that *IRF5* is silenced by DNA methylation in the same cells, suggesting IRF5 is involved in mediating cellular senescence.[22] Here we showed that DAC enhanced p53-induced *IRF5* expression, and that *IRF5* expression was also induced by p63 and p73, suggesting *IRF5* is a target of the p53 gene family. Although, on average, *IRF5* methylation was not significantly higher in primary cancers than in noncancerous tissues, several cases did show high levels of *IRF5* methylation.

We found that *IRF8* expression was down-regulated in gastric cancer cell lines; that DNA methylation was well correlated with gene silencing; and that treating cells with DAC restored *IRF8* expression. This is consistent with earlier reports showing that *IRF8* is silenced in colorectal cancer cell lines in a DNA methylation-dependent manner.[23] In contrast to the data obtained with cell lines, we did not find an increase in *IRF8* methylation in primary gastric cancers, as compared to noncancerous tissues. This is in contrast to earlier studies showing that *IRF8* is methylated in cancers of the colon, esophagus, and nasopharyngus.[24,37] This discrepancy may reflect the different methods used to detect methylation: methylation-specific PCR was used in those earlier studies, whereas we used bisulfate-pyrosequencing. Alternatively, methylation of *IRF8* may be an early event in tumorigenesis, which starts in subsets of gastric epithelial cells. Consistent with that idea, Lee *et al.* reported that *IRF8* is methylated only in some esophageal tissues from esophageal cancer patients. Further study will be necessary to clarify the significance of *IRF8* methylation in primary gastric cancers.

In conclusion, we have shown that *IRF4*, *IRF5*, and *IRF8* are epigenetically silenced in gastric cancer cells. Methylation of *IRF5* was associated with CIMP and EBV infection. Moreover, the high degree of *IRF4* methylation in gastric mucosae from cancer patients suggests that DNA methylation of *IRF4* could be a useful molecular marker for gastric cancer diagnosis and risk assessment.

Acknowledgments

The authors thank Dr William F. Goldman for editing the manuscript. This study was supported in part by Grants-in-Aid for Scientific Research on Priority Areas (M.T., K.I., and T.T.); the Program for Developing Supporting Systems for Upgrading Education and Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (Y.S., M.T.); Grants-in-Aid for Scientific Research (S) from the Japan Society for Promotion of Science (K.I.); a Grant-in-Aid for the Third-term Comprehensive 10-year Strategy for Cancer Control (F.I., M.T.); and Grant-in-Aid for Cancer Research from the Ministry of Health, Labor, and Welfare of Japan (M.T.).

Disclosure Statement

The authors have no conflict of interest.

References

1 Wright PA, Williams GT. Molecular biology and gastric carcinoma. *Gut* 1993; **34**: 145–7.
2 Jones PA, Baylin SB. The epigenomics of cancer. *Cell* 2007; **128**: 683–92.
3 Sato F, Meltzer SJ. CpG island hypermethylation in progression of esophageal and gastric cancer. *Cancer* 2006; **106**: 483–93.
4 Suzuki H, Tokino T, Shinomura Y, Imai K, Toyota M. DNA methylation and cancer pathways in gastrointestinal tumors. *Pharmacogenomics* 2008; **9**: 1917–28.
5 Ushijima T. Detection and interpretation of altered methylation patterns in cancer cells. *Nat Rev Cancer* 2005; **5**: 223–31.
6 Nojima M, Suzuki H, Toyota M *et al.* Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. *Oncogene* 2007; **26**: 4699–713.
7 Sato H, Suzuki H, Toyota M *et al.* Frequent epigenetic inactivation of DICKKOPF family genes in human gastrointestinal tumors. *Carcinogenesis* 2007; **28**: 2459–66.
8 Maruyama R, Akino K, Toyota M *et al.* Cytoplasmic RASSF2A is a proapoptotic mediator whose expression is epigenetically silenced in gastric cancer. *Carcinogenesis* 2008; **29**: 1312–8.
9 Suzuki H, Itoh F, Toyota M, Kikuchi T, Kakiuchi H, Imai K. Inactivation of the 14-3-3 sigma gene is associated with 5′ CpG island hypermethylation in human cancers. *Cancer Res* 2000; **60**: 4353–7.
10 Akino K, Toyota M, Suzuki H *et al.* Identification of DFNA5 as a target of epigenetic inactivation in gastric cancer. *Cancer Sci* 2007; **98**: 88–95.
11 Issa JP. DNA methylation as a therapeutic target in cancer. *Clin Cancer Res* 2007; **13**: 1634–7.
12 Smits KM, Cleven AH, Weijenberg MP *et al.* Pharmacoepigenomics in colorectal cancer: a step forward in predicting prognosis and treatment response. *Pharmacogenomics* 2008; **9**: 1903–16.
13 Hellebrekers DM, Lentjes MH, van den Bosch SM *et al.* GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. *Clin Cancer Res* 2009; **15**: 3990–7.
14 Muller HM, Oberwalder M, Fiegl H *et al.* Methylation changes in faecal DNA: a marker for colorectal cancer screening? *Lancet* 2004; **363**: 1283–5.
15 Maekita T, Nakazawa K, Mihara M *et al.* High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. *Clin Cancer Res* 2006; **12**: 989–95.
16 Nakajima T, Maekita T, Oda I *et al.* Higher methylation levels in gastric mucosae significantly correlate with higher risk of gastric cancers. *Cancer Epidemiol Biomarkers Prev* 2006; **15**: 2317–21.
17 Takaoka A, Tamura T, Taniguchi T. Interferon regulatory factor family of transcription factors and regulation of oncogenesis. *Cancer Sci* 2008; **99**: 467–78.
18 Miyamoto M, Fujita T, Kimura Y *et al.* Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. *Cell* 1988; **54**: 903–13.
19 Tanaka N, Ishihara M, Lamphier MS *et al.* Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. *Nature* 1996; **382**: 816–8.
20 Barnes BJ, Kellum MJ, Pinder KE, Frisancho JA, Pitha PM. Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death. *Cancer Res* 2003; **63**: 6424–31.
21 Mori T, Anazawa Y, Iiizumi M, Fukuda S, Nakamura Y, Arakawa H. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. *Oncogene* 2002; **21**: 2914–8.
22 Li Q, Tang L, Roberts PC *et al.* Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts. *Mol Cancer Res* 2008; **6**: 770–84.
23 Yang D, Thangaraju M, Greeneltch K *et al.* Repression of IFN regulatory factor 8 by DNA methylation is a molecular determinant of apoptotic resistance and metastatic phenotype in metastatic tumor cells. *Cancer Res* 2007; **67**: 3301–9.
24 Lee KY, Geng H, Ng KM *et al.* Epigenetic disruption of interferon-gamma response through silencing the tumor suppressor interferon regulatory factor 8 in nasopharyngeal, esophageal and multiple other carcinomas. *Oncogene* 2008; **27**: 5267–76.
25 Ortmann CA, Burchert A, Holzle K *et al.* Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. *Nucleic Acids Res* 2005; **33**: 6895–905.
26 Yanagihara K, Ito A, Toge T, Numoto M. Antiproliferative effects of isoflavones on human cancer cell lines established from the gastrointestinal tract. *Cancer Res* 1993; **53**: 5815–21.
27 Ishida S, Yamashita T, Nakaya U, Tokino T. Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. *Jpn J Cancer Res* 2000; **91**: 174–80.

doi: 10.1111/j.1349-7006.2010.01581.x

28 Maruyama R, Aoki F, Toyota M *et al.* Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. *Cancer Res* 2006; **66**: 4574–83.
29 Watanabe Y, Toyota M, Kondo Y *et al.* PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. *Clin Cancer Res* 2007; **13**: 4786–94.
30 Sugai T, Habano W, Jiao YF *et al.* Analysis of allelic imbalances at multiple cancer-related chromosomal loci and microsatellite instability within the same tumor using a single tumor gland from colorectal carcinomas. *Int J Cancer* 2005; **114**: 337–45.
31 Kusano M, Toyota M, Suzuki H *et al.* Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. *Cancer* 2006; **106**: 1467–79.
32 Driggers PH, Ennist DL, Gleason SL *et al.* An interferon gamma-regulated protein that binds the interferon-inducible enhancer element of major histocompatibility complex class I genes. *Proc Natl Acad Sci U S A* 1990; **87**: 3743–7.
33 Shou J, Soriano R, Hayward SW, Cunha GR, Williams PM, Gao WQ. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. *Proc Natl Acad Sci U S A* 2002; **99**: 2830–5.
34 Karpf AR, Peterson PW, Rawlins JT *et al.* Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. *Proc Natl Acad Sci U S A* 1999; **96**: 14007–12.
35 Satoh A, Toyota M, Ikeda H *et al.* Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. *Oncogene* 2004; **23**: 8876–86.
36 Reu FJ, Bae SI, Cherkassky L *et al.* Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation. *J Clin Oncol* 2006; **24**: 3771–9.
37 McGough JM, Yang D, Huang S *et al.* DNA methylation represses IFN-gamma-induced and signal transducer and activator of transcription 1-mediated IFN regulatory factor 8 activation in colon carcinoma cells. *Mol Cancer Res* 2008; **6**: 1841–51.
38 Tshuikina M, Jernberg-Wiklund H, Nilsson K, Oberg F. Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma. *Exp Hematol* 2008; **36**: 1673–81.
39 Ahlquist DA. Next generation stool DNA testing: expanding the scope. *Gastroenterology* 2009; **136**: 2068–73.
40 Watanabe Y, Kim HS, Castoro RJ *et al.* Sensitive and specific detection of early gastric cancer using DNA methylation analysis of gastric washes. *Gastroenterology* 2009; **136**: 2149–58.
41 Takeshima H, Yamashita S, Shimazu T, Niwa T, Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. *Genome Res* 2009; **19**: 1974–82.
42 Barnes BJ, Field AE, Pitha-Rowe PM. Virus-induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes. *J Biol Chem* 2003; **278**: 16630–41.
43 Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ, Tainsky MA. Epigenetic silencing of multiple interferon pathway genes after cellular immortalization. *Oncogene* 2003; **22**: 4118–27.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Fig. S1. Real-time PCR analysis of interferon regulatory factor (*IRF*)-*4*, *IRF5*, and *IRF8* expression in gastric cancer cell lines.

Fig. S2. Induction of interferon regulatory factor (*IRF*)-*5* expression by p53 (a) and of *IRF8* expression by interferon (IFN)-γ (b).

Fig. S3. 5-Aza-2′-deoxycytidine (DAC) enhances suppression of cell growth by interferon.

Fig. S4. Methylation analysis of interferon regulatory factor (*IRF*)-*4*, *IRF5*, and *IRF8* after treatment with 5-aza-2′-deoxycytidine (DAC) and/or interferon (IFN).

Fig. S5. Receiver–operator curve (ROC) for interferon regulatory factor (*IRF*)-*4* methylation to discriminate patients with a single gastric cancer from patients with *Helicobacter pylori*-positive chronic gastritis.

Fig. S6. Receiver–operator curve (ROC) curve for interferon regulatory factor (*IRF*)-*4* methylation to discriminate patients with a single or multiple gastric cancers from patients with *Helicobacter pylori*-positive chronic gastritis.

Table S1. Primers used for methylation-specific PCR (MSP) used in this study.

Table S2. Primer sequences used for bisulfite-pyrosequencing and bisulfite-sequencing.

Table S3. High levels of interferon regulatory factor (IRF)-4 methylation are associated with multiple gastric cancers.

Please note: Wiley-Blackwell are not responsible for the content or functionality of any supporting materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.

Breast Cancer Res Treat
DOI 10.1007/s10549-009-0600-1

PRECLINICAL STUDY

Genomic screening for genes upregulated by demethylation revealed novel targets of epigenetic silencing in breast cancer

Tomoko Fujikane · Noriko Nishikawa · Minoru Toyota · Hiromu Suzuki · Masanori Nojima · Reo Maruyama · Masami Ashida · Mutsumi Ohe-Toyota · Masahiro Kai · Toshihiko Nishidate · Yasushi Sasaki · Tousei Ohmura · Koichi Hirata · Takashi Tokino

Received: 4 May 2009 / Accepted: 12 October 2009

Abstract Breast cancer arises through the accumulation of multiple genetic alterations and epigenetic changes such as methylation, which silences gene expression in a variety of cancers. In the present study, we applied genomic screening to identify genes upregulated by the demethylating agent 5-aza-2′-deoxycytidine (DAC) in a human breast cancer cell line (MCF7). We identified 288 genes upregulated and 29 genes downregulated more than five-fold after treatment with DAC, and gene ontology analyses revealed the genes to be involved in immune responses, apoptosis, and cell differentiation. In addition, real-time PCR analysis of ten genes silenced in MCF7 cells confirmed that they are upregulated by DAC, while bisulfite-pyrosequencing analysis confirmed that nine of those genes were silenced by methylation. We also found that treating MCF7 cells with DAC restored induction of DFNA5 by p53, as well as by two other p53 family genes, p63γ and p73β. Introduction of NTN4 into MCF7 cells suppressed cell growth, indicating that NTN4 has tumor suppressive activity. In primary breast cancers, we detected cancer-specific methylation of NTN4, PGP9.5, and DKK3, suggesting that methylation of these genes could be useful markers for diagnosis of breast cancer. Thus, DNA methylation appears to be a common event in breast cancer, and the genes silenced by methylation could be useful targets for both diagnosis and therapy.

Keywords DNA methylation · Epigenetics · Gene expression

Tomoko Fujikane, Noriko Nishikawa, Minoru Toyota, Hiromu Suzuki contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s10549-009-0600-1) contains supplementary material, which is available to authorized users.

T. Fujikane · M. Toyota · H. Suzuki · R. Maruyama · M. Ohe-Toyota · Y. Sasaki · T. Tokino
Department of Molecular Biology, Cancer Research Institute, Sapporo Medical University, Sapporo 060-8556, Japan

T. Fujikane · N. Nishikawa · T. Nishidate · T. Ohmura · K. Hirata
First Department of Surgery, Sapporo Medical University, Sapporo 060-8556, Japan

M. Toyota · H. Suzuki · R. Maruyama
First Department of Internal Medicine, Sapporo Medical University, Sapporo 060-8556, Japan

M. Toyota (✉) · M. Ashida · M. Kai
Department of Biochemistry, Sapporo Medical University, South 1, West 17, Chuo-ku, Sapporo 060-8556, Japan
e-mail: mtoyota@sapmed.ac.jp

M. Nojima
Department of Public Health, Sapporo Medical University, Sapporo 060-8556, Japan

Introduction

Epigenetic changes such as DNA methylation and histone modification are now thought to play a significant role in tumorigenesis. Under normal physiological conditions, DNA methylation is involved in such processes as X-chromosome inactivation, genome imprinting, and suppression of repetitive sequences [1], but genome-wide hypomethylation and regional hypermethylation are also common events in tumors [2]. For example, breast cancer, which continues to be one of the most commonly occurring cancers among women, worldwide [3], is known to arise through the accumulation of multiple genetic and epigenetic DNA alterations. Given that more than 1,000 genes are silenced by

Published online: 27 October 2009

DNA methylation in other types of cancers [4], the targets of epigenetic inactivation in breast cancer have just begun to be identified. To date, analysis of candidate genes for DNA methylation in breast cancer has shown that the targets of epigenetic inactivation include cell cycle regulators such as p16 [5] and 14-3-3 sigma [6], cell adhesion molecules such as E-cadherin [7], cytokines such as HIN-1 [8], genes involved in cell signaling such as RASSF1 [9], proapoptotic genes such as TMS1 [10], genes involved in development such as HOXB13 [11], and transcription factors such as activator protein-2α [12]. Genomic screening approaches using cDNA microarrays, and promoter microarrays identified several novel targets of DNA methylation [13–15]. This makes identification of novel genes epigenetically inactivated in breast cancer an important step toward a better understanding of the pathogenesis of the disease. In the present study, therefore, we applied genomic screening to identify genes silenced by DNA methylation in breast cancer and confirmed the results by quantitative methylation analysis. Our findings suggest that DNA methylation is a common event in breast cancer and that many of the genes silenced by DNA methylation could represent useful targets for both diagnosis and therapy.

Materials and methods

Cell lines and specimens

Five breast cancer cell lines (MCF7, MB435s, MB436, MB468, and SKBR-3) were obtained from the American Type Culture Collection (Manassas, VA) or the Japanese Collection of Research Bioresources (Tokyo, Japan). All cell lines were cultured in appropriate medium supplemented with 10% fetal bovine serum and incubated under a 5% CO_2 atmosphere at 37°C. In addition, 75 breast cancer specimens and 15 breast tissue samples from areas adjacent to tumors were obtaining from Sapporo Medical University Hospital at surgery and stored at −80°C. In accordance with institutional guidelines, all patients gave informed consent prior to collection of the specimens. Genomic DNA was extracted using the phenol/chloroform method. Total RNA was extracted from cell lines using Trizol (Life Technologies, Inc.) according to the manufacturer's instructions.

cDNA microarray analysis

Breast cancer cells (MCF7, MB435s, MB436, MB468, and SKBR-3) were treated with DAC for 72 h, total RNA was extracted and purified using Trizol (Invitrogen) and RNA-easy (Qiagen), after which the RNA samples were quantified using NanoDrop ND-100, the quality was assessed using an Agilent Technologies 2100 Bioanalyzer. The RNA concentration in the samples was >100 ng/μl, and the RNA integrity score was 8–10, with 10 being the highest possible score. Sample amplification and labeling were performed using a Low RNA Input Fluorescent Linear Amplification kit (Agilent Technologies) according to the manufacturer's instructions. Samples (1.65 μg) labeled with Cy3 were hybridized and processed on a 4 × 44 K Whole Human Genome Oligo Microarray. Scanning was performed with an Agilent G2565BA microarray scanner using the settings recommended by Agilent Technologies. After all raw data were normalized, fold-change comparisons and gene set enrichment (BROAD Institute) and gene ontology analyses were performed using GeneSpring GX 10.0. The presence of CpG islands was examined using BLAT (http://genome.brc.mcw.edu/cgi-bin/hgBlat) with previously described criteria [16].

Real-time PCR

Samples (5 μg) of RNA were reverse-transcribed using Superscript III (Invitrogen) to prepare first strand cDNA. For semi-quantitative analysis, real-time PCR was carried out using a 7900 Sequence Detection System (Applied Biosystems). The reaction mixture contained 1× TaqMan Universal PCR Master Mix, primers and probes for each gene and 1 μl of cDNA. GAPDH served as an endogenous control. The Taqman probes used in this study are shown in Supplementary Table 1. Each experiment was done in triplicate.

Methylation analysis

For bisulfite-pyrosequencing, genomic DNA was treated with sodium bisulfite as described previously [17, 18], after which pyrosequencing was performed to assess the methylation status [19]. Bisulfite-PCR primers were designed using PSQ Assay Design software (Biotage, Uppsala, Sweden), and the primers and PCR conditions used were specific for each target gene. After the PCR, the biotinylated strand was captured on streptavidin-coated beads (Amersham Bioscience), and pyrosequencing was performed using PSQ HS Gold SNP reagents and a PSQ HS 96 (Biotage, Uppsala, Sweden). For each gene, the average percentage methylation of the entire CpG island was calculated, and cases in which there was more than 10% methylation were deemed to be positive for methylation. To sequence the bisulfite PCR products, the amplified fragments were cloned into a vector using a TOPO TA cloning kit (Invitrogen), after which a cycle sequencing reaction was carried out using a BigDye terminator kit (Applied Biosystems), and the DNA was sequenced using an ABI 3100 automated sequencer (Applied Biosystems).

Primer sequences used for bisulfite-pyrosequencing and bisulfite-sequencing are shown in Supplementary Table 2.

Infection by adenovirus

The generation, purification, and infection procedures used with replication-deficient recombinant adenovirus containing the p53 (Ad-p53), TAp63γ (Ad-p63γ), TAp73β (Ad-p73β), or the bacterial lacZ gene (Ad-lacZ) were described previously [20]. The relative efficiency of adenoviral infection was determined by X-gal staining of cells infected with the Ad-lacZ (control). At an MOI of 100, 90–100% of the cells were infected (data not shown).

Western blot analysis

Mouse anti-FLAG mAb (M2; Sigma) was used for immunoblotting. Whole cell lysates were prepared by scraping cell monolayers into radioimmunoprecipitation assay buffer without SDS [containing 150 mmol/l NaCl, 50 mmol/l Tris–HCl (pH 7.2), 1% deoxycholic acid, 1% Triton X-100, 0.25 mmol/l EDTA (pH 8.0), protease and phosphatase inhibitors, 5 μg/ml leupeptin, 5 μg/ml aprotinin, 1 μg/ml pepstatin A, 1 mmol/l phenylmethylsulfonyl fluoride, 5 mmol/l NaF, and 100 μmol/l sodium orthovanadate], and protein concentrations were determined (Lowry reagent, Bio-Rad). Equal amounts of protein were separated by SDS-PAGE and transferred to Immobilon P membranes (Millipore).

Chromatin immunoprecipitation assay

Chromatin immunoprecipitation (ChIP) assays were performed as described previously using a ChIP assay kit (Upstate Biotechnologies). Briefly, 2×10^6 cells were cross-linked using 1% formaldehyde solution for 15 min at 37°C. The cells were then lysed in 200 μl of SDS lysis buffer and sonicated to generate 300- to 800-bp DNA fragments. Following centrifugation, the cleared supernatant was diluted tenfold with ChIP dilution buffer, after which 1/50 of the extract volume was used for PCR amplification as the input control. The remaining extract was incubated with a specific antibody for 16 h at 4°C. Immune complexes were precipitated, washed, and eluted as recommended. DNA–protein cross-links were reversed by heating for 4 h at 65°C, after which the DNA fragments were purified and dissolved in 50 μl of Tris–EDTA. One microliter of each sample was then used as a template for PCR amplification. PCR for histone analysis was carried out as described previously [21] using the primers listed in Supplementary Table 2. PCR amplification of *DFNA5* and *MDM2* containing the putative p53RE was also carried out using primers listed in Supplementary Table 2.

Colony formation assays

Colony formation assays were carried out as described previously [22]. Briefly, MCF7 cells (1×10^5 cells) were transfected with 5 μg of pReceiver-M11-NTN4 (EX-U1401-M11, GeneCopeia) or with empty vector using Lipofectamine 2000 according to manufacturer's instructions. Cells were then plated on 60-mm culture dishes and selected for 14 days in 0.6 mg/ml G418, after which the colonies that formed were stained with Giemsa and counted using National Institutes of Health IMAGE software.

Statistics

To compare methylation levels between tumors and normal tissues, *t* tests were performed for all samples, and paired *t* tests were performed for matched samples from the same patients. Receiver operating characteristic (ROC) curves were constructed based on the levels of NTN4, PGP9.5, and DKK3 methylation, and *P* values were calculated by comparing the ROC curves to a reference curve. ANOVAs with post hoc Games-Howell tests were performed to compare methylation levels at different cancer stages. A scatter plot was constructed by plotting levels of FKBP6 methylation against tumor size, and a Pearson's correlation coefficient was calculated for these values. Values of $P < 0.05$ were considered significant. All statistical calculations were performed using SPSSJ 15.0 (SPSS Japan Inc.).

Results

Identification of genes upregulated by DAC

The global changes in gene expression induced by DAC in MCF7 breast cancer cells were examined using an Agilent Whole Genome microarray that covers 44,000 transcripts of human genes (Supplementary Fig. 1). As compared with mock-treated cells, 288 genes were upregulated and 29 genes were downregulated more than fivefold by DAC in these cancer cells (Supplementary Tables 3, 4). Four genes (SFRP1, DKK3, DFNA5, TAC1) were recently shown to be silenced by DNA methylation in breast cancer [15, 23–25]. To identify biological processes significantly affected by demethylation, we used gene ontology analysis to assess the function of the 288 upregulated genes. Detailed results are shown in Supplementary Table 5. Treating the cells with DAC led to significant upregulation of genes involved in immune responses, the extracellular region, and cytokine activity. We also conducted a gene set enrichment analysis using functional annotation tools (Supplementary Table 6). Among 26 selected gene sets, genes involved in cell differentiation, cell development, defense responses,

apoptosis, and signal transduction were enriched in DAC-treated cells, as compared to mock-treated cells.

Expression analysis of genes identified by microarray

Database analysis revealed that out of 288 genes upregulated by DAC, 155 contain CpG islands in the 5′ end of the gene (Supplementary Table 3). We next selected ten genes known from earlier work to be cancer-related and to have CpG islands in their 5′ ends (Fig. 1). The selected genes were DFNA5, SFRP1, DKK3, PGP9.5, and LOXL4, which were all previously shown to be silenced by DNA methylation in various types of tumors [26–30]; NTN4, which encodes a member of the netrin family involved in the negative regulation of angiogenesis [31]; TRIM50, which encodes an E3 ubiquitin ligase [32]; FKBP6, which encodes an immunophilin family protein [33]; PON1, which encodes an arylesterase and whose polymorphisms are known to be associated with prostate cancer [34]; and OSBPL3, which encodes an oxysterol-binding protein that plays a role in cell adhesion [35]. Real-time PCR analysis revealed that the expression levels of all these genes were low or negligible in MCF7 cells, whereas high levels of expression—i.e., an expression ratio against GAPDH >0.01—were detected for DFNA5, SFRP1, OSBPL3, NTN4, PGP9.5, and LOXL4 in normal breast tissue; cell lines other than MCF7 showed various levels of expression (Supplementary Fig. 2). For DKK3, FKBP6, PON1, and TRIM50, expression was low—i.e., an expression ratio against GAPDH < 0.01—in normal breast tissue, and cell lines showed various levels of expression (Supplementary Fig. 3). Treatment with DAC restored expression of these genes in cell lines in which expression was otherwise low or negligible (Supplementary Fig. 3).

Methylation analysis of ten genes in breast cancer cell lines

To confirm methylation-dependent gene silencing, we next used bisulfite-pyrosequencing to examine the methylation status of the ten genes. This enabled us to quantify the methylation of multiple CpG sites (Fig. 2). The primers and probes were designed to detect methylation in the region around the transcription start sites. Dense methylation of nine genes (SFRP1, DFNA5, DKK3, PGP9.5, OSBPL3, NTN4, TRIM50, FKBP6, and PON1) was detected in MCF7 cells, strongly suggesting that DNA methylation is the cause of gene silencing. Various levels of methylation were detected in four other cell lines and was also associated with gene silencing (Figs. 1, 2; Supplementary Figs. 2, 3). That methylation of LOXL4 was not detected means that LOXL4 is silenced by a mechanism other than DNA methylation.

Fig. 1 Real-time PCR analysis of genes upregulated by DAC. The expression status of DFNA5, SFRP1, DKK3, FKBP6, LOXL4, OSBPL3, NTN4, PGP9.5, PON1, and TRIM50 was confirmed by real-time PCR. The cell lines and tissues examined are shown below the columns. Cell lines were treated for 72 h with either mock (−) or 1.0 μM DAC. The integrity of the cDNA was assessed by comparing the CT values for the genes of interest with that of GAPDH. *Columns* means of three experiments, *bars* SE

We next performed bisulfite-sequencing analysis to obtain detailed methylation profiles of the CpG sites in the region around the transcription start site of DFNA5 gene. We examined 45 CpG sites and found that DFNA5 was densely methylated in MCF7 cells, which do not express DFNA5. By contrast, little or no methylation was detected in MDA-MB435s, MDA-MB436, MDA-MB-468, and SK-Br-3 cells, which do express DFNA5 (Fig. 3). Thus, the results obtained with bisulfite-sequencing are consistent with both the bisulfite-pyrosequencing data and the DFNA5 expression status.

Restoration of p53-dependent transcription of DFNA5 by demethylation

It was recently reported that DFNA5 is a target gene for p53 [36]. We therefore tested whether demethylation of DFNA5 in MCF7 cells would restore its transcriptional activation by p53 and/or by two other p53 family genes, TAp63γ and TAp73β. When cells were infected with Ad-p53, Ad-p63γ, or Ad-p73β, expression of FLAG-tagged p53 family proteins was detected (Fig. 4a). In addition, p21, a cyclin-dependent inhibitor, was induced by all three vectors (Fig. 4a). We then examined expression of DFNA5 in MCF7 cells with or without treatment with DAC. We found that treating MCF7 cells with DAC restored induction of DFNA5 by p53 family genes, especially by p63, suggesting that DFNA5 is a target of the p53 family, not specifically p53, itself (Fig. 4b). We then performed ChIP assays to determine whether p63γ directly interacts with the p53 response element of DFNA5 (RE-DFNA5) (Fig. 4c). PCR amplification of the ChIP products revealed that one DNA fragment containing RE-DFNA5 was present in the immunoprecipitated complex with p63γ. As a control, we confirmed that p63γ binds to the p53 response element of MDM2 in vivo. These results indicate that DFNA5 can be upregulated by p63γ through direct interaction with RE-DFNA5.

Tumor suppressive activity of NTN4

Netrins and their receptors have been shown to be involved in tumorigenesis [37]. To test whether NTN4 suppresses growth of breast cancer cells, we performed colony formation assays using MCF7 cells, which express negligible levels NTN4. We found that introduction of a plasmid


DFNA5/GAPDH
OSBPL3/GAPDH
SFRP1/GAPDH
NTN4/GAPDH
DKK3/GAPDH
PGP9.5/GAPDH
FKBP6/GAPDH
PON1/GAPDH
LOXL4/GAPDH
TRIM50/GAPDH
5-aza-dC
MCF7
MDA-MB 435s
MDA-MB 436
MDA-MB 468
SK-Br-3
Normal breast



Fig. 2 Representative results of bisulfite-pyrosequencing of DFNA5 (**a**) and SFRP1 (**b**). Bisulfite-pyrosequencing was carried out using DNA from breast cancer cell lines and primary breast cancer specimens. Examined were the regions upstream from the transcription start site (DFNA5: −85 to −97; SFRP1: −65 bp to −44 bp). *Gray columns* depict regions of CpG sites, and the percentage methylation at each CpG site is shown on the *top*. *Y*-axis, signal peaks expressed as a proportion of the number of nucleotides incorporated. *X*-axis, the nucleotides incorporated. Cell lines and specimens are shown below the *columns*

containing NTN4 cDNA significantly suppressed colony growth, suggesting that NTN4 does indeed have tumor suppressive activity (Fig. 5a, b).

Comparison of methylation and clinicopathological features of patients with primary breast cancer

Of the nine aforementioned genes silenced by DNA methylation in primary breast cancer, seven showed significantly higher levels of methylation in cancerous tissues than in normal breast tissues ($P < 0.001$ for NTN4, PGP9.5, DKK3, OSBPL3, SFRP1, DFNA5; $P < 0.01$ for PON1, Fig. 6a; Supplementary Table 7). Methylation was also examined in paired samples of cancerous and adjacent normal breast tissues from 15 patients. Methylation of NTN4 ($P < 0.001$), PGP9.5 ($P < 0.001$), DKK3 ($P = 0.006$), and PON1 ($P = 0.031$) was significantly higher in the tumor tissue than in the adjacent breast tissue (Fig. 6b; Supplementary Table 8). The clinical usefulness of DNA methylation in distinguishing breast cancer from noncancerous tissue was confirmed by analyzing ROC curves (Fig. 6c; Supplementary Table 9). Methylation of NTN4, DKK3, and PGP9.5 showed highly discriminative ROC curve profiles, which clearly distinguished breast cancer from normal breast tissue (NTN4: $p < 0.001$; DKK3: $P < 0.001$; PGP9.5: $P < 0.001$). When we used 16%